Creation of a long-acting nanoformulated dolutegravir

Creation of a long-acting nanoformulated dolutegravir

Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly...

Full description

Bibliographic Details
Main Authors: Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman
Format: Article
Language:English
Published: Nature Portfolio 2018-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-02885-x

Internet

https://doi.org/10.1038/s41467-018-02885-x

Similar Items